Literature DB >> 31309521

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Giuseppe Mulè1, Alessandra Sorce2, Emilio Nardi3, Giulio Geraci2, Santina Cottone2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31309521     DOI： 10.1007/s11739-019-02149-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  20 in total

1.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Authors:  Kevin Damman; Mauro Gori; Brian Claggett; Pardeep S Jhund; Michele Senni; Martin P Lefkowitz; Margaret F Prescott; Victor C Shi; Jean L Rouleau; Karl Swedberg; Michael R Zile; Milton Packer; Akshay S Desai; Scott D Solomon; John J V McMurray
Journal:  JACC Heart Fail       Date:  2018-04-11       Impact factor: 12.035

Review 2.  Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction.

Authors:  Hannah Clark; Henry Krum; Ingrid Hopper
Journal:  Eur J Heart Fail       Date:  2013-12-11       Impact factor: 15.534

3.  Neprilysin inhibitors preserve renal function in heart failure.

Authors:  Fiona Bodey; Ingrid Hopper; Henry Krum
Journal:  Int J Cardiol       Date:  2014-11-06       Impact factor: 4.164

4.  Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.

Authors:  Adriaan A Voors; Mauro Gori; Licette C Y Liu; Brian Claggett; Michael R Zile; Burkert Pieske; John J V McMurray; Milton Packer; Victor Shi; Martin P Lefkowitz; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2015-02-06       Impact factor: 15.534

Review 5.  Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.

Authors:  Mauro Gori; Maurizio Volterrani; Massimo Piepoli; Michele Senni
Journal:  Int J Cardiol       Date:  2016-06-23       Impact factor: 4.164

Review 6.  Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.

Authors:  M Volpe; G Tocci; A Battistoni; S Rubattu
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-06-23

7.  Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.

Authors:  Milton Packer; Brian Claggett; Martin P Lefkowitz; John J V McMurray; Jean L Rouleau; Scott D Solomon; Michael R Zile
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-13       Impact factor: 32.069

Review 8.  The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor.

Authors:  Giovanni Cerasola; Santina Cottone; Giuseppe Mulè
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

9.  Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Authors:  Richard Haynes; Parminder K Judge; Natalie Staplin; William G Herrington; Benjamin C Storey; Angelyn Bethel; Louise Bowman; Nigel Brunskill; Paul Cockwell; Michael Hill; Philip A Kalra; John J V McMurray; Maarten Taal; David C Wheeler; Martin J Landray; Colin Baigent
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.